

# Questionnaire for patients treated with intravenous Treprostinil via an external infusion pump and central venous catheter (CVC)

This patient questionnaire is a mandatory part of the approval of Treprostinil Tillomed Solution For Infusion. This document is part of the additional risk-minimisation measures implemented to reduce the risk of occurrence of catheter-related blood stream infections when Treprostinil Tillomed Solution For Infusion is <u>administered by intravenous continuous infusion</u> via an external infusion pump and a central venous catheter (CVC).

The other risk minimisation measures include a healthcare professional guide and a patient brochure. Copies of all these materials are available via the electronic Medicines Compendium (eMC) website - <a href="https://www.medicines.org.uk/emc/">https://www.medicines.org.uk/emc/</a>

Prescribers and patients are asked to complete this short patient questionnaire which will help assess the ease with which patients are able to apply the risk minimisation activities and identify any particular difficulties that they experience which the clinical team can address.

Completed questionnaires should be sent via email to PVUK@tillomed.co.uk

To be filled by the physician:						
Reason for completing questionnaire:						
☐ Check patient knowledge after initial education ☐ Check patient knowledge after 3-6 months therapy ☐ Check patient knowledge after catheter-related blood stream infection*						
* Report any suspected blood stream infections by e-mail to PVUK@tillomed.co.uk						
Treating Physician:						
Treatment Centre:						
Date (questionnaire filled on):						
Duration of the intravenous infusion therapy						
Patient Initials: Patient Identifier:						
Patient Age:   Patient Gender:   female						
Who filled out the questionnaire?  □ Patient □ Medical professional (together with the patient)						



The following questions should be answered by the patient:

Return the completed questionnaire to the clinical team responsible for your care

1.	•	ation and training	g provided by	inistering your intravenous infusion your clinical team? team to address any issues/concern					
2.	Central venous catheter-related blood stream infections are a recognised risk of								
	intravenous infusion treprostinil treatment								
	□ True	□ False	☐ Do not k	now					
3.	Prior to preparing your infusion or handling your infusion system/catheter do you wash								
	your hands ar	nd follow aseptic	techniques a	s advised by your clinical team?					
	□ No	□ Sometimes	□ Often	□ Always					
4.	Prior to preparing your infusion and replacing infusion system items (filters, hubs, tubing								
	etc) do you check the expiry dates for the items and medication you will be using?								
	□ No	□ Sometimes	□ Often	□ Always					
5.	•	n of Treprostinil in formation is on the		oer milliliter (mg/ml) do you use?					
6.	6. What quantity of undiluted Treprostinil in millilitres (ml) do you take from the vial of the above mentioned strength?								
7.	Which diluent do you use?								
		•		(w/v) sodium chloride for injection					
8. With what quantity of the above diluent in millilitres (ml) do you mix the taken undiluted Treprostinil?									
9.	What is the obtained total amount of diluted Treprostinil solution in millilitres (ml) when you have carried out all the necessary dilution steps?								
10.	What is your current infusion rate in milliliters per hour (ml/h)?								
11.	What is the m	aximum duration	of use of the	diluted product that you prepare f	or infusion?				
	□ 24 hours	□ 48 hou	rs 🗆 🗆	72 hours					



12.	How often should	d you replace the conte	ents of yo	our drug container and the infusion tube?	?				
	□ every 24 hours	□ every 48 hours	□ every	y 72 hours					
13.	How often should you replace the split-septum closed hub device of your infusion								
	system?								
	□ every 3 days	□ every 5 days	□ every	y 7 days					
14.	Does your infusion system already contain a filter?								
	□ Yes	□ No							
15.	If you answered "No" to Q14: Do you install a separate filter when you change your								
	infusion system?								
	□ No	□ Sometime □ C	Often	□ Always					
16.	What type of dressing do you use at the catheter insertion site?								
	☐ Sterile Gauze ☐ Sterile Transparent Dressing								
17.	How often do you change this dressing at the catheter insertion site?								
	□ every 2 days	□ every 7 days		☐ Other (please specify)					
18.	If the dressing has become damp, loosened, or soiled or after examination of the catheter								
	insertion site, what should be done?								
	☐ It should be washed with plain water								
	☐ It should be replaced								
	□ Do not know								
19.	Do you go swimming?								
	□ Yes	□ No							
20.	Do you use a waterproof dressing to keep the connection between your catheter and the								
	infusion system dry when bathing/showering?								
	□ Yes	□ No							
21.	Describe the signs of infection that you should watch for daily:								
			_		_				
22.	_	u do if you suspect in ical team/doctor immedia		associated with your catheter/treatment  ☐ Do nothing	:?				
			,	ŭ					



To be filled by the physician/clinical team responsible for the care of the patient:						
Review from responsible clinical team:  Date of review:						
☐ Patient has demonstrated appropriate understanding/knowledge of their treatment						
☐ Patient has NOT demonstrated appropriate understanding/knowledge of their treatment (please complete free text entry below)						
Describe the gap in knowledge the patient demonstrated:						
Has the patient been retrained to address the gap in knowledge demonstrated:  ☐ Yes ☐ No						
Name of member of the clinical team reviewing this completed questionnaire:						
Sign and date:						
PLEASE SEND THE COMPLETED QUESTIONNAIRE TO PVUK@Tillomed.co.uk						